ClinicalTrials.gg
RecruitingNCT02804269BiobankUpdated Nov 17, 2026

Molecular and Imaging Studies of Cardiovascular Health and Disease

An observational study in Healthy, Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy, sponsored by National Heart Centre Singapore. Recruiting at 1 site in Singapore. Open to participants aged 16 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Heart Centre Singapore · Observational

How we know

Updated Nov 17, 2026Enrollment updatedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,000
Ages
16 Years to 90 Years
Sex
All
01

Study summary

Biobank is a program which collects biological samples, health information and imaging data from consented patients and stored them at the core facility. These information would be used to study the molecular, imaging and outcome studies of cardiovascular health and disease.

Read the detailed description

This program recruits patient from National Heart Centre Singapore and collects their biological sample, health information and imaging data.The donated biospecimens will be stored indefinitely and used for any future research on molecular, imaging and outcome studies of cardiovascular health and disease.The same biological samples and imaging data will be obtained from consented healthy volunteers for comparison.

02

Conditions studied

  • Healthy
  • Dilated Cardiomyopathy
  • Hypertrophic Cardiomyopathy
  • Ischemic Heart Disease

Keywords

  • Healthy Volunteer
  • Dilated cardiomyopathy
  • Hypertrophic cardiomyopathy
  • ischemic heart disease
  • Cardiovascular Magnetic Resonance Imaging
03

In context

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

This study's planned enrollment of 6,000 is above the median of 250 across 97 observational studies indexed under Cardiomyopathy, Dilated.

Browse Cardiomyopathy, Dilated studies →

Lead sponsor

National Heart Centre Singapore is the lead sponsor of 63 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patient will be recruited from primary care clinic and outpatient clinics from the National Heart Centre Singapore. For healthy volunteer, they will be recruited through poster and advertisement.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

There is no inclusion/exclusion criteria except for the age limit as this is a repository program.

Inclusion criteria

Inclusion Criteria:

•Subject aged ≥ 16 years and ≤ 90 years.

Exclusion criteria

Exclusion Criteria:

•No

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy Volunteer

    Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement

    Other: Cardiovascular Magnetic Resonance · Other: Fatmass measurement

  • Dilated Cardiomyopathy

    Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement

    Other: Cardiovascular Magnetic Resonance · Other: Fatmass measurement

  • Hypertrophic cardiomyopathy

    Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement

    Other: Cardiovascular Magnetic Resonance · Other: Fatmass measurement

  • Ischemic heart disease with reduced EF

    Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement

    Other: Cardiovascular Magnetic Resonance · Other: Fatmass measurement

  • Ischemic heart disease with normal EF

    Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement

    Other: Cardiovascular Magnetic Resonance · Other: Fatmass measurement

Interventions

  • OtherCardiovascular Magnetic Resonance

    For the evaluation of heart function and structure of the cardiovascular system.

  • OtherFatmass measurement

    It utilizes a scale machine to measure the body fat and skeletal muscle percentage

06

What researchers measure

Primary outcomes

  1. Numbers of genetic variation in genes known to cause inherited cardiac condition and circulating biomarkers which are linked with DNA changes using advanced sequencing and informatics approaches

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Jul 2033 and a completion of Jul 2033. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2016
First posted
Jun 17, 2016
Start
Jul 2013
Primary completionEst.
Jul 2033
CompletionEst.
Jul 2033
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
5000→6000
Nov 17, 2026
Contact
Study contact changed: person changed (no phone or email listed). See the current contact
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Enrollment 5000→6000
    Contact Study contact changed: person changed (no phone or email listed). See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02804269
Lead sponsor
National Heart Centre Singapore
Responsible party
Sponsor
First posted
Jun 17, 2016
Start date
Jul 2013
Primary completion
Jul 2033 (estimated)
Completion
Jul 2033 (estimated)
Last update
Nov 17, 2026

Study contacts

Siew Ching Kong
Contact
kong.siew.ching@nhcs.com.sg
(65) 67042275
Calvin Chin, MBBS
Contact
Calvin Chin, MBBS
principal investigator · National Heart Centre Singapore

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion